Factor VIII polymer conjugates

Details Factor VIII polymer conjugates Factor VIII polymer conjugates

2011-01-20

2011-11-29

Hobbs, Lisa J (Department: 1657)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S380000, C530S381000, C424S530000

Reexamination Certificate

active

08067543

ABSTRACT:
The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4757006 (1988-07-01), Toole, Jr. et al.
patent: 4970300 (1990-11-01), Fulton et al.
patent: 5122614 (1992-06-01), Zalipsky
patent: 5153265 (1992-10-01), Shadle et al.
patent: 5198349 (1993-03-01), Kaufman
patent: 5198493 (1993-03-01), Holmberg et al.
patent: 5250421 (1993-10-01), Kaufman et al.
patent: 5298643 (1994-03-01), Greenwald
patent: 5492821 (1996-02-01), Callstrom et al.
patent: 5621039 (1997-04-01), Hallahan et al.
patent: 5733873 (1998-03-01), Osterberg et al.
patent: 5919766 (1999-07-01), Osterberg et al.
patent: 5969040 (1999-10-01), Hallahan et al.
patent: 6037452 (2000-03-01), Minamino et al.
patent: 6048720 (2000-04-01), Dalborg et al.
patent: 6183738 (2001-02-01), Clark
patent: 6586398 (2003-07-01), Kinstler et al.
patent: 6692931 (2004-02-01), Reutter et al.
patent: 6743908 (2004-06-01), Filpula et al.
patent: 6806063 (2004-10-01), Pedersen et al.
patent: 6872393 (2005-03-01), Whitlow et al.
patent: 6913915 (2005-07-01), Ensor et al.
patent: 7118737 (2006-10-01), Kochendoerfer et al.
patent: 7199223 (2007-04-01), Bossard et al.
patent: 7230081 (2007-06-01), Jensen et al.
patent: 7338788 (2008-03-01), Pedersen et al.
patent: 2003/0143596 (2003-07-01), Bentley et al.
patent: 2005/0106658 (2005-05-01), Defrees
patent: 2006/0286634 (2006-12-01), Kingsman et al.
patent: 2007/0244301 (2007-10-01), Siekmann et al.
patent: 2009/0076237 (2009-03-01), Turecek et al.
patent: 0306968 (1989-03-01), None
patent: 0605963 (1994-07-01), None
patent: 1 260 582 (2002-11-01), None
patent: 1258497 (2002-11-01), None
patent: WO-91/09122 (1991-06-01), None
patent: WO-92/16555 (1992-10-01), None
patent: WO-94/05332 (1994-03-01), None
patent: WO-94/15625 (1994-07-01), None
patent: WO-94/15626 (1994-07-01), None
patent: WO-96/40731 (1996-12-01), None
patent: WO-00/23114 (2000-04-01), None
patent: WO-00/48635 (2000-08-01), None
patent: WO-2004/075923 (2004-09-01), None
patent: WO-2004/089280 (2004-10-01), None
patent: WO-2006/071801 (2006-07-01), None
patent: WO-2008/025856 (2008-03-01), None
patent: WO-2008/074032 (2008-06-01), None
Abuchowski et al., Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.Cancer Biochem. Biophys.7: 175-86 (1984).
Baxter announces collaborations to develop longer acting forms of blood clotting factors.Baxter News(online), Sep. 29, 2005.
Bi et al., Target disruption of the mouse factor VIII gene produces a model of Haemophilia A.Nat. Genet.10: 119-21 (1995).
Caliceti et al., Pharmacokinetics of pegylated interferons: What is misleading?Digest. Liver Dis.36(Suppl. 3): S334-9 (2004).
Harris et al., Effect of pegylation on pharmaceuticals.Nat. Rev. Drug Discovery.2: 214-21 (2003).
Kozlowski et al., Development of pegylated interferons for the treatment of chronic Hepatitis C.BioDrugs.15(7): 419-29 (2001).
Nektar Advanced PEGylation Catalog 2005-2006, p. 30 (2005).
Nektar Advanced PEGylation Price List 2005-2006, p. 11 (2005).
NOF Corporation DDS Catalogue, p. 58 (2005).
Roberts et a., Chemistry for peptide and protein pegylationAdv. Drug Del. Rev.54: 459-76 (2002).
Rosen et al., Assay of factor VIII: C with a chromogenic substrate.Scand J. Haematol.33(Suppl. 40): 139-45 (1984).
Rostin et al., B-domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol.Bioconjugate Chem.11: 387-96 (2000).
Saenko et al., Strategies towards a longer acting factor VIII.Haemophilia.12: 42-51 (2006).
Sakuragawa et al., Studies on the stability of factor VIII modified by polyethylene glycol.Acta Med. Biol.36:1-5 (1988).
Seffernick et al., Melamine deaminase and atrazine chlorohydrolase: 98% identical but functionally different.J. Bacteriology.2405-10 (2001).
Severs et al., Characterization of PEGylated factor VIII molecules.Blood.108: 11-12 (2006). Abstract.
Study shows molecular size and structure of PEG interferon molecules, as used in pegintron(R), affect antiviral activity in vitro.Hispanic PR Wire, Oct. 28, 2003.
Tsubery et al., Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification.J. Biol. Chem.279(37): 38118-24 (2004).
Tsutsumi et al., Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.Proc. Natl. Acad. Sci. USA.97: 8548-53 (2000).
Urrutigoity et al., Biocatalysis in organic solvents with a polymer-bound horseradish peroxidase.Biocatalysis.2: 145-9 (1989).
Veronese et al., Bioconjugation in pharmaceutical chemistry.IL Farmaco.54: 497-516 (1999).
Wells et al., Additivity of mutational effects in proteins.Biochemistry.29(37): 8509-17 (1990).
Wilchek et al., Labeling glycoconjugates with hydrazide reagents.Methods Enzymol.138: 429-42 (1987).
Zalipsky et al., Hydrazide derivatives of poly(ethylene glycol) and their bioconjugates. Poly(ethylene glycol) Chemistry and Biological Applications. Chapter 21, pp. 318-341 (1997).
International Search Report, PCT/US2007/007560, European Patent Office, dated Sep. 18, 2007.
Written Opinion of the International Search Authority, PCT/US2007/007560, European Patent Office, dated Sep. 18, 2007.
International Search Report, PCT/US2009/052103, European Patent Office, dated Feb. 12, 2010.
Written Opinion of the International Searching Authority, PCT/US2009/052103, European Patent Office, dated Feb. 12, 2010.

Affiliated with

Also associated with

Rating

Factor VIII polymer conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Factor VIII polymer conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factor VIII polymer conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4280198